CRH-Alpha-2 Macroglobulin Complex for Extended Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Corticotropin-releasing hormone (CRH) formulations have a limited effective biological half-life and stability, leading to sub-optimal efficacy and a short therapeutic window, making it challenging to maintain persistent levels for effective treatment of various disorders.
Innovation Solution
A stabilised complex of CRH and alpha-2 macroglobulin is developed, where alpha-2 macroglobulin is present in a specific concentration to protect CRH, enhancing its stability and biological half-life, and the formulation is processed using microfiltration and nanofiltration under cooled conditions to prevent aggregation and degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If CRH is administered alone, then the therapeutic effect is achieved, but the biological half-life is limited to approximately 4 minutes
Solution Approach 1:
Alpha-2-macroglobulin serves as an intermediary carrier protein that binds to CRH, protecting it from rapid degradation and clearance. This mediator extends the circulation time of CRH from 4 minutes to at least 24 hours while maintaining its therapeutic activity, resolving the contradiction between short half-life and efficacy reliability
Solution Approach 2:
The invention creates a composite formulation consisting of CRH complexed with alpha-2-macroglobulin. This composite structure combines the therapeutic properties of CRH with the protective and carrier functions of alpha-2-macroglobulin, achieving both extended half-life and maintained efficacy simultaneously
2Stability of the object's composition
If CRH formulation is stored without stabilization, then the formulation is simple, but the stability is limited leading to sub-optimal efficacy
Solution Approach 1:
Alpha-2-macroglobulin acts as a stabilizing intermediary that protects CRH from degradation during storage and circulation. The complex formation provides conformational protection and prevents aggregation, significantly enhancing formulation stability without requiring additional stabilizing excipients or complex storage conditions
Solution Approach 2:
The invention utilizes the specific binding affinity between CRH and alpha-2-macroglobulin at physiological conditions to stabilize the formulation. By changing the molecular state of CRH from free to complexed, the formulation achieves enhanced stability against degradation and aggregation without increasing structural complexity
3Duration of action of moving object
If constant infusion of CRH is used to maintain persistent levels, then the therapeutic window is extended, but the method is impractical outside hospital setting
Solution Approach 1:
The CRH-alpha-2-macroglobulin complex is pre-formed and stabilized before administration, incorporating the half-life extension function directly into the formulation. This preliminary complexation eliminates the need for continuous infusion infrastructure, allowing single-dose or intermittent dosing that maintains persistent CRH levels for at least 24 hours, making treatment practical in outpatient settings
Solution Approach 2:
The alpha-2-macroglobulin in the formulation autonomously performs the function of extending CRH half-life without requiring external intervention or monitoring. The complex self-regulates CRH release and protection in circulation, eliminating the need for hospital-based constant infusion systems and enabling convenient administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stabilised CRH formulation achieves extended plasma half-life of at least 24 hours, allowing for sustained therapeutic effects and increased bioavailability, effectively treating a wide range of disorders with improved stability and efficacy.
Implementation Method 1
alpha-2 macroglobulin is present in a specific concentration to protect CRH, enhancing its stability and biological half-life
Implementation Method 2
the formulation is processed using microfiltration and nanofiltration under cooled conditions to prevent aggregation and degradation
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present invention relates to a CRH formulation having improved stability/ efficacy. The improved CRH formulation is particularly suitable for treatment of various disorders. The invention also relates to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation.